Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article Report
  • Published:

Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'

Nature Clinical Practice Oncology volume 6, page E1 (2009)Cite this article

Access through your institution
Buy or subscribe

Arising from: Bostjan Seruga and Ian Tannock (2008) Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 5: 574–576 doi:10.1038/ncponc1180

Sir,

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Segura S and Tannock IA (2008) Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 5: 574–576

    Article  Google Scholar 

  2. Chuu CP et al. (2005) Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen stimulated phenotype in athymic mice. Cancer Res 65: 2082–2084

    Article  CAS  Google Scholar 

  3. Sabnis GJ et al. (2008) Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68: 4518–4524

    Article  CAS  Google Scholar 

  4. Jordan VG (2008) The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer – Survival or death? J Clin Oncol 26: 3073–3082

    Article  CAS  Google Scholar 

  5. Schibler MJ and Cabral F (1986) Taxol-dependent mutants of Chinese Hamster Ovary cells with alterations in α- and β-tubulin J Cell Biol 102: 1522–1531

    Article  CAS  Google Scholar 

  6. Kavallaris M et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282–1293

    Article  CAS  Google Scholar 

  7. Slater LM et al. (1992) Novel nucleolar and nuclear morphology in a vincristine-dependent human leukemia cell line (L100). Exp Cell Res 198: 170–174

    Article  CAS  Google Scholar 

  8. Yang CP et al. (2005) A Higly resistant epothilone B resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 4: 987–995

    Article  CAS  Google Scholar 

  9. Cabral F (1983) Isolation of Chinese Hamster Ovary cell mutants requiring the continuous presence of taxol for cell divison. J Cell Biol 97: 22–29

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Children's Cancer Institute Australia for Medical Research, Pharmacoproteomics Program, PO Box 81 (High St), Randwick, NSW 2031, Australia EPasquier@ccia.unsw.edu.au

Authors and Affiliations

  1. Children's Cancer Institute Australia for Medical Research, Pharmacoproteomics Program, PO Box 81 (High St), Randwick, NSW 2031, Australia

    Nicolas André & Eddy Pasquier

Authors
  1. Nicolas André
    View author publications

    Search author on:PubMed Google Scholar

  2. Eddy Pasquier
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

André, N., Pasquier, E. Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat Rev Clin Oncol 6, E1 (2009). https://doi.org/10.1038/ncponc1317

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc1317

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing